Aptose Biosciences Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William G. Rice
- Full Time Employees
- 35
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 251 Consumers Road Toronto ON Canada M2J 4R3
- IPO Date
- Mar 16, 1992
- CIK
- 0000882361
- Website
- aptose.com
- Similar Companies
- Business
- Aptose Biosciences Inc. Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines that address unmet needs in oncology, particularly hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and non-Hodgkin’s lymphomas (NHL); its small molecule cancer therapeutics pipeline features tuspetinib (HM43239 or TUS), an oral myeloid kinase inhibitor targeting key oncogenic pathways for relapsed or refractory AML, frontline triplet therapy with venetoclax plus azacitidine in newly diagnosed AML, and MDS; and luxeptinib (CG-806 or LUX), an oral dual lymphoid and myeloid kinase inhibitor that is mutation-agnostic against FLT3 and BTK for relapsed or refractory B-cell malignancies and AML resistant to approved targeted therapies. Originally incorporated as Lorus Therapeutics Inc. in 1986 in Toronto, Ontario, Canada, the company rebranded as Aptose Biosciences Inc. in 2014 with a strategic pivot to targeted kinase inhibitors for hematologic cancers and maintains headquarters in San Diego, California. Aptose operates primarily in North America with global clinical trial collaborations and recently entered into an arrangement agreement for acquisition by Hanmi Pharmaceutical Co. Ltd. announced on November 19, 2025, which supports continued advancement of the TUSCANY Phase 1/2 study for tuspetinib triplet therapy in AML while providing a premium to minority shareholders and marking Hanmi’s entry into North American operations.
Aptose Reports First Quarter 2026 Results
Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?
Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?
Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Should You Sell?
Aptose Announces Auditor Not Standing for Re-Appointment
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Aptose Reports Year End 2024 Results and Corporate Highlights
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Aptose Announces Reverse Share Split
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering